期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 145, 期 1, 页码 101-106出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1365-2141.2009.07595.x
关键词
mTOR; autoimmunity; signal transduction; rapamycin
类别
资金
- United States Immunodeficiency Network [N01-A1-30070]
We hypothesized that sirolimus, an mTOR inhibitor, may be effective in patients with autoimmune lymphoproliferative syndrome (ALPS) and treated patients who were intolerant to or failed other therapies. Four patients were treated for autoimmune cytopenias; all had a rapid complete or near complete response. Two patients were treated for autoimmune arthritis and colitis, demonstrating marked improvement. Three patients had complete resolution of lymphadenopathy and splenomegaly and all patients had a reduction in double negative T cells, a population hallmark of the disease. Based on these significant responses, we recommend that sirolimus be considered as second-line therapy for patients with steroid-refractory disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据